InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,486.34
(
0.15%
)
US TECH 100
19,206.00
(
-0.05%
)
Dow Jones
39,108.79
(
-0.05%
)
Brent Oil
85.02
(
0.65%
)
Bitcoin
61,738.00
(
1.53%
)
Post# of 252398
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: DewDiligence post# 46749

Tuesday, 05/15/2007 11:46:02 PM

Tuesday, May 15, 2007 11:46:02 PM

Post# of 252398
Dew—I agree with you that biogenerics are a risk to large cap biotechs. However, based on AMGN’s current valuation, the market seems to be valuing AMGN as a pharmaceutical company rather than a high PE biotech. Like big pharma, AMGN will be subject to generic competition, and it would seem that the market is already taking this risk into account (I know what you think about the efficient market hypothesis-LOL).

Regards,

biophud
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up